Synamp: New generation antibiotics to treat drug resistant infections

Synamp: New generation antibiotics to treat drug resistant infections

On November 23rd, at the Dutch LifeSciences Conference videos of our 6 Venture Challenge teams delivering their final pitches were presented to the audience. Followed by Chretien Herben, Programme Director LS@W, who announced the winning team of this Fall edition.
The pitches were the result of a very successful Venture Challenge with strong and promising teams. Eventually the Jury decided to point out Synamp Pharmaceuticals as winning team.

Synamp is addressing a large societal challenge of antibiotic resistance. Synamp’s goal is the discovery and development of entirely new classes of antibiotics capable of selectively targeting and killing bacterial cells via novel modes of action. This strategy and the very experienced Board of advisors connected to the startup, convinced the jury they chose well in pointing out Synamp as this edition’s winner.

More about Synamp >>

Next to Synamp, the other Venture Challenge Fall 2015 teams were U-Pact, STENTIT, Novioscan, Exbiome and MaMaLoc.

Stay up to date with the latest news!

Newsletter subscribe